Company intelligence / Profile preview

TrueLab Biopharmaceutical

Ownership: Private
Development stage: Other

Overview

TrueLab Biopharmaceutical is an emerging Chinese biotech company with at least one pipeline asset, TL-001. As of March–May 2025, the company’s lead candidate entered a Phase 1 clinical trial in healthy adults to evaluate safety and pharmacokinetics. The mechanism of action and therapeutic area remain undisclosed. No clinical results have been published yet.

Therapeutic areas: Other
Modalities: Unknown
Industry: Biotech

Drug pipeline

8 assets

TL-001

7 more assets in the full pipeline.

Beyond the preview

Go deeper on TrueLab Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TrueLab Biopharmaceutical.